Jad Chahoud, Associate Member, Department of Genitourinary Oncology at Moffitt Cancer Center, shared on X about a recent paper by Emily Grist et al. published on Cell:
“In advanced Prostate Cancer, biology matters!
14-year follow-up of >1,500 patients
- Low AR signaling=poor outcomes
- Decipher predicts benefit with docetaxel
- PTEN loss → worse survival, docetaxel-sensitive
More info.”
Title: Tumor transcriptome-wide expression classifiers predict treatment sensitivity in advanced prostate cancers
Authors: Emily Grist, Peter Dutey-Magni, Marina A. Parry, Larissa Mendes, Ashwin Sachdeva, James A. Proudfoot, Anis A. Hamid, Mazlina Ismail, Sarah Howlett, Stefanie Friedrich, Lia DePaula Oliveira, Laura Murphy, Christopher Brawley, Oluwademilade Dairo, Sharanpreet Lall, Yang Liu, Daniel Wetterskog, Anna Wingate, Karolina Nowakowska, Leila Zakka, Claire L. Amos, Nafisah B. Atako, Victoria Wang, Hannah L. Rush, Robert J. Jones, Hing Leung, William R. Cross, Silke Gillessen, Chris C. Parker, Teresa Marafioti, Alfonso Urbanucci, Matthew Fittall, Edward M. Schaeffer, Daniel E. Spratt, David Waugh, Thomas Powles, Matthew R. Sydes, Felix Y. Feng, Daniel M. Berney, Mahesh K.B. Parmar, Noel W. Clarke, Elai Davicioni, Tamara L. Lotan, Christopher J. Sweeney, Louise C. Brown, Nicholas D. James, Gerhardt Attard.
More posts featuring Jad Chahoud.